enGene’s CEO, Ron Cooper, returned to BizTV’s The Big Biz Show last month to raise awareness about non-muscle invasive bladder cancer (NMIBC) and highlight how enGene is committed to improving patient outcomes through an innovative investigational treatment. Learn more about enGene and our clinical development program here: https://engene.com/.
enGene
Biotechnology Research
St-Laurent, Quebec 12,946 followers
On a mission to mainstream genetic medicines through delivery of therapeutics to mucosal tissues & other organs
About us
At enGene, we are at the vanguard of a new era in genetic medicine: Our novel Dually Derivatized Oligochitosan® (DDX) gene delivery platform is designed to enable localized delivery of multiple gene cargos, including RNA and DNA, directly to mucosal tissues and other organs — potentially overcoming the limitations of viral-based gene therapies and advancing gene therapy beyond rare genetic diseases into the mainstream of clinical practice. Our breakthrough Dually Derivatized Oligochitosan® (DDX) platform opens possibilities for streamlining the use of genetic medicines in the treatment of serious diseases, especially diseases afflicting mucosal tissues. Our lead product candidate, EG-70 (detalimogene voraplasmid), is a non-viral immunotherapy in development to treat non-muscle invasive bladder cancer (NMIBC), a disease with a significant patient burden, high clinical needs, and massive healthcare system economic impact. Based on its preliminary efficacy and safety profile and ease of administration by urologists, EG-70, which is currently in a pivotal trial, can potentially benefit patients across a wide variety of clinical settings. As enGeneers, we are boldly focused on patients' needs. We are a team of passionate experts with extensive experience in drug development and commercialization across oncology, respiratory, and several other therapeutic areas. Nasdaq: ENGN
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- St-Laurent, Quebec
- Type
- Public Company
- Founded
- 1999
- Specialties
- gene therapy, urology, oncology, immunotherapy, NMIBC, non-muscle invasive bladder cancer, bladder cancer, DNA, RNA, genetic medicines, Mucosal tissues, non-viral gene therapy, EG-70, cytokine IL-12, interleukin-12, and drug development
Locations
-
Primary
Get directions
7171 Frederick Banting
St-Laurent, Quebec H4S 1Z9, CA
-
Get directions
200 5th Ave
Waltham, Massachusetts 02451, US
Employees at enGene
Updates
-
Thank you to all who viewed our three poster presentations at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium! We were thrilled to be able to highlight the ongoing clinical developments of the LEGEND study for patients with non-muscle invasive bladder cancer (#NMIBC). Check out highlights from our time onsite below! #ASCOGU #GU25
-
-
#ICYMI, Shreyas Joshi, M.D., MPH, Acting Director of the Bladder Cancer Program at Emory University School of Medicine was featured in Urology Times, highlighting the ongoing LEGEND clinical trial for patients with non-muscle invasive bladder cancer (NMIBC) and the potential impact of a new treatment option. Watch the full interview here: https://lnkd.in/efZXNvzF
-
-
Today, we will share three poster presentations at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, highlighting the ongoing LEGEND study for patients with non-muscle invasive bladder cancer (#NMIBC). Learn more about our upcoming presentations: https://lnkd.in/ePgySvE2 #ASCOGU #GU25
-
enGene’s Chief Strategy and Operations Officer, Alex Nichols, Ph.D., will be presenting at the Oppenheimer & Co. Inc. 35th Annual Healthcare Life Sciences Conference. We look forward to connecting with the investor community and sharing updates on enGene’s efforts to improve health outcomes for patients with non-muscle invasive bladder cancer (NMIBC). Read the full press release here: https://lnkd.in/gtndTU3i.
-
-
Patients with non-muscle invasive bladder cancer (NMIBC) face limited treatment options with high burden – often becoming unresponsive to treatment and facing disease progression, with many requiring removal of the bladder as a last resort. This #WorldCancerDay and every day, we stand unwavering in our commitment to advance genetic medicines to overcome these limitations, and are actively enrolling our LEGEND clinical trial to investigate a new option for #NMIBC patients. Learn more about the LEGEND study, by visiting https://engene.com/
-
enGene reposted this
I am immensely proud of the work the team at enGene puts into the development of our novel, investigational, non-viral genetic medicine for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). We are looking forward to sharing our latest updates at #GU25.
We are looking forward to sharing three poster presentations at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium. Our presentations will highlight recent clinical data and a trial-in-progress summary for our pivotal LEGEND trial for non-muscle invasive bladder cancer (NMIBC). Learn more about our upcoming presentations: https://lnkd.in/ePgySvE2 #ASCOGU #GU25
-
We are looking forward to sharing three poster presentations at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium. Our presentations will highlight recent clinical data and a trial-in-progress summary for our pivotal LEGEND trial for non-muscle invasive bladder cancer (NMIBC). Learn more about our upcoming presentations: https://lnkd.in/ePgySvE2 #ASCOGU #GU25
-
We're #hiring a new Associate Director/ Director Biostatistics in Waltham, Massachusetts. Apply today or share this post with your network.
-
We look forward to having our CEO Ron Cooper, our CMO Raj S. Pruthi, MD, MHA, FACS, our CFO Ryan Daws, and our Chief Strategy and Operations Officer Alex Nichols, PhD in San Francisco to meet with healthcare industry leaders, investors, and other stakeholders during the 43rd Annual J.P. Morgan Healthcare Conference. To learn more about enGene and our clinical development program exploring a potentially new way to treat non-muscle invasive bladder cancer (NMIBC), visit: https://engene.com/
-